All Medical News

• 

  All Medical News

  ECCO 2016: Specialists gathered to discuss new data and current issues and solutions in IBD. Professor David Rubin (Chicago, USA), ECCO President Professor Séverine Vermeire (Leuven, Belgium), Professor Stefan Schreiber (Kiel, Germany) and Dr Peter Irving (London, UK) took time out to discuss with IBD.Update what they are excited about what’s coming up in the near future for patients with IBD.

  Written by Lorraine Carolan | 17 May 2016

• 

  All Medical News

  ECCO 2016: Mechanisms by which inflammation resolves

  Written by Lorraine Carolan | 13 May 2016

  Silvio Danese, Humanitas Clinical and Research Hospital, Milan, Italy. Article by Maria Dalby – The current paradigm for managing inflammatory conditions is to suppress the inflammatory response by… read more.

• 

  All Medical News

  ECCO 2016: IOIBD: Disease severity definition in IBD. Professor Laurent Peyrin-Biroulet (Nancy University Hospital, France) discusses a new disease severity score initiated by the IOIBD

  Written by Lorraine Carolan | 12 May 2016

• 

  All Medical News

  ECCO 2016: Dr Charlie Lees (Edinburgh, UK), Dr Ailsa Hart and Marian O’Connor (Harrow, UK), Dr James Lindsay (London, UK) and Dr Peter Irving (London, UK) discuss the new therapeutic landscape in IBD since changes to guidance by NICE and SMC over the last year

  Written by Lorraine Carolan | 11 May 2016

  New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.

• 

  All Medical News

  ECCO 2016: Professor Jean-Frederic Colombel (New York, USA) and Dr James Lindsay (Barts and the London NHS Trust, UK) discuss new data from the GEMINI programme showing patient populations that do well and long term data with vedolizumab

  Written by Lorraine Carolan | 10 May 2016

  Update from the GEMINI study programme – by Maria Dalby Jean-Frédéric Colombel, Mount Sinai Hospital, New York, USA The GEMINI study programme is a large phase-3 clinical trial… read more.

• 

  All Medical News

  ECCO 2016: Dr Charlie Lees (Edinburgh, UK) discusses in the video and article below the factors influencing the decision to stop treatment and discussed whether it may be possible to predict relapse using currently available methods

  Written by Lorraine Carolan | 9 May 2016

  Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.

• 

  All Medical News

  ECCO 2016: Professor David Rubin from Chicago discusses the challenges of UC management and optimising biological therapy

  Written by Lorraine Carolan | 6 May 2016

  Management of ulcerative colitis: putting patients at the centre – by Maria Dalby Iris Dotan (Tel Aviv Sourasky Medical Centre, Israel), Peter Irving (Guy’s and St Thomas’ NHS… read more.

• 

  All Medical News

  ECCO 2016: Professor Séverine Vermeire (Leuven, Belgium) discusses new patient guidelines for Crohn’s disease and ulcerative colitis which were released at this year’s 11th Congress of ECCO in Amsterdam, and Helen Terry (CCUK) discusses how they might be rolled out to patients in the UK.

  Written by Lorraine Carolan | 5 May 2016

  ECCO-EFCCA Patient Guidelines – by Maria Dalby Marco Greco, Milan, Italy; Séverine Vermeire, University Hospital of Leuven, Belgium; Salvatore Leone, Palermo, Italy; Paolo Gionchetti, University of Bologna, Italy; Martin Kojinov, Sofia, Bulgaria; Axel… read more.

• 

  All Medical News

  ECCO 2016: Professor Laurent Peyrin-Biroulet (Nancy, France), Professor Jean-Frederic Colombel (New York, USA), Marian O’Connor (Harrow, UK) and Dr Charlie Lees (Edinburgh, UK) give their highlights of the 11th Congress of ECCO

  Written by Lorraine Carolan | 4 May 2016

• 

  All Medical News

  Herceptin plus lapatinib shows “amazing” potential in breast cancer

  Written by Bruce Sylvester | 3 May 2016

  by Bruce Sylvester: Researchers report that Herceptin (trastuzamab) plus lapatinib can shrink breast cancer tumors in less than two weeks. The findings were reported in March at the… read more.

• 

  All Medical News

  Loneliness and isolation increase risk of heart disease and stroke

  Written by Bruce Sylvester | 2 May 2016

  by Bruce Sylvester: In high income countries, loneliness and social isolation appear to increase the risk of stroke or coronary artery disease by about 30 per cent, researchers… read more.

• 

  All Medical News

  Smoking cessation drugs do not increase serious psychiatric side effects

  Written by Bruce Sylvester | 29 Apr 2016

  by Bruce Sylvester: Smoking cessation treatment with varenicline and bupropion does increase serious neuropsychiatric side effects, researchers reported in The Lancet on April 22, 2016.